BAYZED HEALTH

Bayzed Health opened lower and rallied in the morning session, last trading at HK$2.96 as of 09:36 BJ, up 5.34% from prior close of HK$2.81, with an intraday range of HK$2.82 to HK$2.94, likely driven by today's announcement of a joint company secretary appointment. The stock has a trailing P/E of -272x and P/B of 2.32x, with a market cap of approximately HK$3.9 billion. While Q4 2025 operating revenue fell 7.78% YoY to HK$303 million, net profit surged 902.88% YoY to HK$8.15 million, and EPS rose to HK$0.0068. However, the price remains weak, down 23.91% YTD and 85.11% from its 52-week high of HK$19.88, and at HK$2.96 it trades below both the 20-day MA (HK$3.469) and 60-day MA (HK$4.605).

Bai Ze Medical Group staged a low-open rally in the morning session, closing at HK$3.13 as of 11:00 BJ, up 5.74% from the previous close of HK$2.96, driven mainly by a technical rebound after two consecutive days of sharp declines. The stock hit an intraday high of HK$3.13, while the low of HK$2.94 occurred just one minute after the open. The current price is 84.31% below the 52-week high of HK$19.88, but still 17.74% above the 52-week low of HK$2.65, and well below both the 20-day MA (HK$4.5) and 60-day MA (HK$4.944), reflecting ongoing valuation pressure. In Q4 2025, net profit surged 902.88% YoY to approximately HK$8.15 million, with EPS of HK$0.0068, but revenue fell 7.78% YoY and net profit margin was only 2.69%, indicating fragile earnings quality. However, the stock had plunged over 14% and 8% on June 8 and June 9 respectively, and today's rebound was modest, with turnover of only about HK$7.37 million, suggesting thin participation.

Bai Ze Medical Group (2609.HK) staged a sharp afternoon recovery from a morning low of HK$2.86, closing at HK$3.04, up 4.8% from the previous close of HK$2.90, though it briefly hit an intraday high of HK$3.33, reflecting intense long-short divergence. The stock has been volatile recently, with a single-day plunge of over 14% last week, making today's bounce likely a technical rebound from oversold levels. Financially, Q4 2025 revenue was about HK$303 million, down 7.78% YoY, but net profit surged 902.88% YoY to HK$8.15 million, with a net profit margin of only 2.69%. At HK$3.04, the stock remains 84.71% below its 52-week high of HK$19.88, down 21.85% YTD, and well below its 20-day moving average of HK$4.594. However, the recovery brings it 14.72% above the 52-week low of HK$2.65, suggesting a possible near-term floor.

BAYZED HEALTH extended afternoon session losses, closing at HK$2.91, down 12.35% from the previous close of HK$3.32, with a session low of HK$2.91 near the 52-week trough, 85.4% below the 52-week high of HK$19.88. Opening at HK$3.27, the stock slid sharply in the morning session and continued to deteriorate in the afternoon, with total volume of 18.26 million shares and a turnover rate of 1.39%. Recent negative news weighed on sentiment, including a report of an 8% decline before the morning session and a 14% plunge the previous day. Despite this, the latest earnings show two consecutive quarters of improvement—Q4 net profit rose 902.9% YoY to HK$8.15 million, with EPS of HK$0.0068 (up 898.4% YoY), while revenue of HK$303 million was only 7.8% lower YoY. The current price is well below the 20-day MA of HK$4.80 and 60-day MA of HK$5.02, and the stock is down 25.2% year-to-date. However, its P/B ratio of 2.28x remains above most Hong Kong healthcare peers, and the P/E ratio is negative.

BaiZe Medical Group plunged over 14% on July 3, closing at HKD 3.32, driven by intensified selling in the afternoon session with an intraday low of HKD 3.31. The stock is now 83.3% below its 52-week high of HKD 19.88, while year-to-date losses reached 14.65%. The closing price sits well below both the 20-day MA of HKD 4.913 and the 60-day MA of HKD 5.045, reflecting pronounced technical weakness. Despite a 902.88% surge in Q4 2025 net profit to HKD 8.15 million and positive EPS of HKD 0.0068, revenue still contracted 7.78% YoY and net margin remained thin at 2.69%, so earnings improvements failed to offset sentiment. Overhang from previous HKD 188 million in loans extended to a partner hospital and a shareholder stake sale netting HKD 18.4 million continued to weigh, though the stock trades at a PB of 2.6 and a market cap of approximately HKD 4.38 billion, suggesting some valuation cushion.